Exploration of Immunology

Table 1. The 13 P. gingivalis proteins tested with 142 human leukocyte antigen (HLA)-I alleles and 192 HLA-II alleles.

Number	Protein	UniProt ID	Amino acid (AA)	HLA-I		HLA-II
Number	Protein	UniProt ID	Amino acid (AA)	N (9-mer)	N tested (142 HLA-I alleles)	N (15-mer)	N tested (192 HLA-II alleles)
1	Minor fimbrium subunit Mfa1	B2RHG1	563	555	78,810	549	105,408
2	Minor fimbrium anchoring subunit Mfa2	B2RHG2	324	316	44,872	310	59,520
3	Minor fimbrium tip subunit Mfa3	B2RHG3	446	438	62,196	432	82,944
4	Minor fimbrium tip subunit Mfa4	B2RHG4	333	325	46,150	319	61,248
5	Minor fimbrium subunit Mfa5	B2RHG5	1,228	1,220	173,240	1,214	233,088
6	Gingipain R2 (RgpA)	B2RKU0	736	728	103,376	722	138,624
7	Lys-gingipain (Kgp)	B2RLK2	1,723	1,715	243,530	1,709	328,128
8	Gingipain R1 (RgpB)	B2RM93	1,703	1,695	240,690	1,689	324,288
9	Major fimbrium subunit FimA	B2RH54	383	375	53,250	369	70,848
10	Major fimbrium subunit FimB	A0PA81	303	295	41,890	289	55,488
11	Major fimbrium subunit FimC	B2RH57	453	445	63,190	439	84,288
12	Major fimbrium subunit FimD	B2RH58	670	662	94,004	656	125,952
13	Major fimbrium subunit FimE	B2RH59	550	542	76,964	536	102,912
Total	-	-	-	9,311	1,322,162	9,233	1,772,736

Return to article view

Supplementary materials

The supplementary tables for this article are available at: https://www.explorationpub.com/uploads/Article/file/1003271_sup_1.pdf.

Declarations

Disclaimer

The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

Author contributions

LMJ: Conceptualization, Investigation, Funding acquisition, Writing—original draft, Writing—review & editing. MS: Data curation, Software, Writing—review & editing. APG: Data curation, Formal analysis, Visualization, Funding acquisition, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

Apostolos P. Georgopoulos, who is the Editorial Board Member and Guest Editor of Exploration of Immunology, and Lisa M. James, who is the Guest Editor of Exploration of Immunology, had no involvement in the decision-making or the review process of this manuscript. Matthew Sanders declares no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All data used were retrieved from freely accessible websites and, as such, are publicly and freely available (http://tools.iedb.org/mhci/). Other datasets that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

Partial funding for this study was provided by the University of Minnesota (the American Legion Brain Sciences Chair and the Kunin Chair in Women’s Healthy Brain Aging) and the U.S. Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Mysak J, Podzimek S, Sommerova P, Lyuya-Mi Y, Bartova J, Janatova T, et al. Porphyromonas gingivalis: Major Periodontopathic Pathogen Overview. J Immunol Res. 2014;2014:476068. [DOI] [PubMed] [PMC]

Fiorillo L, Cervino G, Laino L, D’Amico C, Mauceri R, Tozum TF, et al. Porphyromonas gingivalis, Periodontal and Systemic Implications: A Systematic Review. Dent J. 2019;7:114. [DOI] [PubMed] [PMC]

Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10:717–25. [DOI] [PubMed] [PMC]

Curtis MA, Garnett JA, Darveau RP. The Keystone‐Pathogen Hypothesis Updated: The Role of Porphyromonas gingivalis in Periodontitis. J Periodontal Res. 2025;[Epub ahead of print]. [DOI] [PubMed]

de Jongh CA, de Vries TJ, Bikker FJ, Gibbs S, Krom BP. Mechanisms of Porphyromonas gingivalis to translocate over the oral mucosa and other tissue barriers. J Oral Microbiol. 2023;15:2205291. [DOI] [PubMed] [PMC]

Martínez-García M, Hernández-Lemus E. Periodontal Inflammation and Systemic Diseases: An Overview. Front Physiol. 2021;12:709438. [DOI] [PubMed] [PMC]

Mei F, Xie M, Huang X, Long Y, Lu X, Wang X, et al. Porphyromonas gingivalis and Its Systemic Impact: Current Status. Pathogens. 2020;9:944. [DOI] [PubMed] [PMC]

Kanagasingam S, Chukkapalli SS, Welbury R, Singhrao SK. Porphyromonas gingivalis is a Strong Risk Factor for Alzheimer’s Disease. J Alzheimers Dis Rep. 2020;4:501–11. [DOI] [PubMed] [PMC]

Fu Y, Xu X, Zhang Y, Yue P, Fan Y, Liu M, et al. Oral Porphyromonas gingivalis Infections Increase the Risk of Alzheimer’s Disease: A Review. Oral Health Prev Dent. 2023;21:7–16. [DOI] [PubMed] [PMC]

10.

Huang Z, Hao M, Shi N, Wang X, Yuan L, Yuan H, et al. Porphyromonas gingivalis: a potential trigger of neurodegenerative disease. Front Immunol. 2025;16:1482033. [DOI] [PubMed] [PMC]

11.

Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:eaau3333. [DOI] [PubMed] [PMC]

12.

Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat Rev Rheumatol. 2017;13:606–20. [DOI] [PubMed]

13.

Li Y, Guo R, Oduro PK, Sun T, Chen H, Yi Y, et al. The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis. Front Cell Infect Microbiol. 2022;12:956417. [DOI] [PubMed] [PMC]

14.

Li C, Yu R, Ding Y. Association between Porphyromonas Gingivalis and systemic diseases: Focus on T cells-mediated adaptive immunity. Front Cell Infect Microbiol. 2022;12:1026457. [DOI] [PubMed] [PMC]

15.

How KY, Song KP, Chan KG. Porphyromonas gingivalis: An Overview of Periodontopathic Pathogen below the Gum Line. Front Microbiol. 2016;7:53. [DOI] [PubMed] [PMC]

16.

Płonczyńska A, Prucsi Z, Sochalska M, Potempa J. Porphyromonas Gingivalis Virulence Factors and their Role in Undermining Antimicrobial Defenses and Host Cell Death Programs in the Pathobiology of Chronic Periodontal Disease. Adv Microbiol. 2025;64:3–23. [DOI]

17.

Guo Y, Nguyen KA, Potempa J. Dichotomy of gingipains action as virulence factors: from cleaving substrates with the precision of a surgeon’s knife to a meat chopper-like brutal degradation of proteins. Periodontol 2000. 2010;54:15–44. [DOI] [PubMed] [PMC]

18.

Xu W, Zhou W, Wang H, Liang S. Roles of Porphyromonas gingivalis and its virulence factors in periodontitis. Adv Protein Chem Struct Biol. 2020;120:45–84. [DOI] [PubMed] [PMC]

19.

Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015;15:30–44. [DOI] [PubMed] [PMC]

20.

Hajishengallis G, Diaz PI. Porphyromonas gingivalis: Immune Subversion Activities and Role in Periodontal Dysbiosis. Curr Oral Health Rep. 2020;7:12–21. [DOI] [PubMed] [PMC]

21.

Trowsdale J, Knight JC. Major Histocompatibility Complex Genomics and Human Disease. Annu Rev Genomics Hum Genet. 2013;14:301–23. [DOI] [PubMed] [PMC]

22.

van Deutekom HW, Keşmir C. Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most? Immunogenetics. 2015;67:425–36. [DOI] [PubMed] [PMC]

23.

Davenport MP, Quinn CL, Chicz RM, Green BN, Willis AC, Lane WS, et al. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain. Proc Natl Acad Sci U S A. 1995;92:6567–71. [DOI] [PubMed] [PMC]

24.

Nguyen AT, Szeto C, Gras S. The pockets guide to HLA class I molecules. Biochem Soc Trans. 2021;49:2319–31. [DOI] [PubMed] [PMC]

25.

Blum JS, Wearsch PA, Cresswell P. Pathways of Antigen Processing. Annu Rev Immunol. 2013;31:443–73. [DOI] [PubMed] [PMC]

26.

Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022;22:751–64. [DOI] [PubMed]

27.

Marrack P, Kappler J. The T Cell Receptor. Science. 1987;238:1073–9. [DOI] [PubMed]

28.

Alcover A, Alarcón B, Di Bartolo V. Cell Biology of T Cell Receptor Expression and Regulation. Annu Rev Immunol. 2018;36:103–25. [DOI] [PubMed]

29.

Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18:485–97. [DOI] [PubMed]

30.

Manz BN, Jackson BL, Petit RS, Dustin ML, Groves J. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. Proc Natl Acad Sci U S A. 2011;108:9089–94. [DOI] [PubMed] [PMC]

31.

Sykulev Y, Brunmark A, Jackson M, Cohen RJ, Peterson PA, Eisen HN. Kinetics and affinity of reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity. 1994;1:15–22. [DOI] [PubMed]

32.

Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response. Immunity. 1996;4:565–71. [DOI] [PubMed]

33.

Valitutti S, Müller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide–MHC complexes. Nature. 1995;375:148–51. [DOI] [PubMed]

34.

Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol. 1995;154:567–76. [DOI]

35.

Groscurth P, Filgueira L. Killing Mechanisms of Cytotoxic T Lymphocytes. News Physiol Sci. 1998;13:17–21. [DOI] [PubMed]

36.

Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, et al. The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates Immunodominance. Immunity. 2005;23:29–40. [DOI] [PubMed]

37.

Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature. 2002;419:845–9. [DOI] [PubMed]

38.

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002.

39.

Ollila J, Vihinen M. B cells. Int J Biochem Cell Biol. 2005;37:518–23. [DOI] [PubMed]

40.

Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol. 2016;11:137–54. [DOI] [PubMed] [PMC]

41.

Castellino F, Germain RN. COOPERATION BETWEEN CD4⁺AND CD8⁺T CELLS: When, Where, and How. Annu Rev Immunol. 2006;24:519–40. [DOI] [PubMed]

42.

Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity. 1995;2:555–9. [DOI] [PubMed]

43.

Fearon DT, Locksley RM. The Instructive Role of Innate Immunity in the Acquired Immune Response. Science. 1996;272:50–3. [DOI] [PubMed]

44.

Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 SYSTEM OF T CELL COSTIMULATION. Annu Rev Immunol. 1996;14:233–58. [DOI] [PubMed]

45.

Liu Y, Janeway CA Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A. 1992;89:3845–9. [DOI] [PubMed] [PMC]

46.

Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997;9:4–9. [DOI] [PubMed]

47.

Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol. 1998;10:351–3. [DOI] [PubMed]

48.

Olsen I, Taubman MA, Singhrao SK. Porphyromonas gingivalis suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer’s disease. J Oral Microbiol. 2016;8:33029. [DOI] [PubMed] [PMC]

49.

Romero-Fonseca AZ, Sir-Mendoza F, Rey-Buitrago M. Gene Variants in TNF-α and HLA in Phenotypes of Chronic and Aggressive Periodontitis: A Systematic Review. Basic Sci Biotechnol Bioinform. 2025;44:1–23. [DOI]

50.

Menezes CFS, Lage LM, Santos LGS, Nascimento GC, Magalhães M, Facundo A, et al. HLA Polymorphisms Linked to the Severity and Extent of Periodontitis in Patients with Type 1 Diabetes from a Brazilian Mixed Population. Int J Environ Res Public Health. 2025;22:512. [DOI] [PubMed] [PMC]

51.

Chowdhury M, Agrawal N, Kundu D, Biswas N. Association of human leukocyte antigens Class I and Class II antigens with chronic periodontitis in East India. J Indian Soc Periodontol. 2017;21:494–8. [DOI] [PubMed] [PMC]

52.

Reichert S, Altermann W, Stein JM, Schaller HG, Machulla HK, Schulz S. Individual Composition of Human Leukocyte Antigens and Periodontopathogens in the Background of Periodontitis. J Periodontol. 2013;84:100–9. [DOI] [PubMed]

53.

Stein JM, Machulla HK, Smeets R, Lampert F, Reichert S. Human leukocyte antigen polymorphism in chronic and aggressive periodontitis among Caucasians: a meta‐analysis. J Clin Periodontol. 2008;35:183–92. [DOI] [PubMed]

54.

Stein JM, Machulla HK, Deschner J, Fickl S, Jockel-Schneider Y, Tamm M, et al. Prevalence of periodontitis in individuals with human leukocyte antigens (HLA) A9, B15, A2, and B5. Clin Oral Investig. 2016;20:703–10. [DOI] [PubMed]

55.

Damgaard C, Danielsen AK, Enevold C, Massarenti L, Nielsen CH, Holmstrup P, et al. Porphyromonas gingivalis in saliva associates with chronic and aggressive periodontitis. J Oral Microbiol. 2019;11:1653123. [DOI] [PubMed] [PMC]

56.

Rafiei M, Kiani F, Sayehmiri K, Sayehmiri F, Tavirani M, Dousti M, et al. Prevalence of Anaerobic Bacteria (P.gingivalis) as Major Microbial Agent in the Incidence Periodontal Diseases by Meta-analysis. J Dent (Shiraz). 2018;19:232–42. [PubMed] [PMC]

57.

Arévalo-Caro C, Romero-Sánchez C, Garavito-Rodríguez E. Relation between anti-Porphyromonas gingivalis antibody titers and HLA-DRB1 neutral alleles in individuals with rheumatoid arthritis. Acta Odontol Scand. 2021;80:131–9. [DOI] [PubMed]

58.

Hajishengallis G. Immune Evasion Strategies of Porphyromonas gingivalis. J Oral Biosci. 2011;53:233–40. [DOI]

59.

Zheng S, Yu S, Fan X, Zhang Y, Sun Y, Lin L, et al. Porphyromonas gingivalis survival skills: Immune evasion. J Periodontal Res. 2021;56:1007–18. [DOI] [PubMed]

60.

Hurley CK, Kempenich J, Wadsworth K, Sauter J, Hofmann JA, Schefzyk D, et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. HLA. 2020;95:516–31. [DOI] [PubMed] [PMC]

61.

Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449–54. [DOI] [PubMed] [PMC]

62.

IEDB Analysis Resource [Internet]. IEDB; c2005–2026 [cited 2026 Jan 7]. Available from: http://tools.iedb.org/mhci/

63.

Charonis S, James LM, Georgopoulos AP. In silico assessment of binding affinities of three dementia-protective Human Leukocyte Antigen (HLA) alleles to nine human herpes virus antigens. Curr Res Transl Med. 2020;68:211–6. [DOI] [PubMed]

64.

Charonis SS, Tsilibary EP, Georgopoulos AP. SARS-CoV-2 Virus and Human Leukocyte Antigen (HLA) Class II: Investigation in silico of Binding Affinities for COVID-19 Protection and Vaccine Development. J Immunol Sci. 2020;4:12–23. [DOI] [PubMed] [PMC]

65.

Charonis SA, Tsilibary EP, Georgopoulos AP. In silico investigation of binding affinities between human leukocyte antigen class I molecules and SARS-CoV-2 virus spike and ORF1ab proteins. Explor Immunol. 2021;1:16–26. [DOI] [PubMed] [PMC]

66.

Cerundolo V, Elliott T, Elvin J, Bastin J, Rammensee HG, Townsend A. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur J Immunol. 1991;21:2069–75. [DOI] [PubMed]

67.

Engelhard VH. Structure of Peptides Associated with Class I and Class II MHC Molecules. Annu Rev Immunol. 1994;12:181–207. [DOI] [PubMed]

68.

Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 1992;358:764–8. [DOI] [PubMed]

69.

Omran A, Amberg A, Ecker GF. Exploring diverse approaches for predicting interferon-gamma release: utilizing MHC class II and peptide sequences. Brief Bioinform. 2025;26:bbaf101. [DOI] [PubMed] [PMC]

70.

Istrail S, Florea L, Halldórsson BV, Kohlbacher O, Schwartz RS, Yap VB, et al. Comparative immunopeptidomics of humans and their pathogens. Proc Natl Acad Sci U S A. 2004;101:13268–72. [DOI] [PubMed] [PMC]

71.

Nielsen M, Lundegaard C, Blicher T, Peters B, Sette A, Justesen S, et al. Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan. PLoS Comput Biol. 2008;4:e1000107. [DOI] [PubMed] [PMC]

72.

Dhanik A, Kirshner JR, MacDonald D, Thurston G, Lin HC, Murphy AJ, et al. In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy. BMC Bioinform. 2016;17:286. [DOI] [PubMed] [PMC]

73.

Barquera R, Collen E, Di D, Buhler S, Teixeira J, Llamas B, et al. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide. HLA. 2020;96:277–98. [DOI] [PubMed] [PMC]

74.

Salminen A, Hyvärinen K, Ritari J, Caetano A, Kambur O, Mäntylä P, et al. Genetic Loci Associated With Periodontitis: The FinnGen Study Based on National Health Registers. J Clin Periodontol. 2025;52:1263–75. [DOI] [PubMed] [PMC]

75.

Sedghi LM, Bacino M, Kapila YL. Periodontal Disease: The Good, The Bad, and The Unknown. Front Cell Infect Microbiol. 2021;11:766944. [DOI] [PubMed] [PMC]

76.

Abdelkader H, Salminen A, Leskelä J, Palviainen T, Salasuo E, Paju S, et al. GWAS of Serum Antibodies to Microbial Biomarker Species of Periodontitis. J Dent Res. 2026;105:866–74. [DOI] [PubMed]

77.

Heidler TV, Ernits K, Ziolkowska A, Claesson R, Persson K. Porphyromonas gingivalis fimbrial protein Mfa5 contains a von Willebrand factor domain and an intramolecular isopeptide. Commun Biol. 2021;4:106. [DOI] [PubMed] [PMC]

78.

Messina BM, Grippaudo C, Polizzi A, Blasi A, Isola G. The Key Role of Porphyromonas gingivalis in the Pathogenesis of Periodontitis Linked with Systemic Diseases. Appl Sci. 2025;15:6847. [DOI]

79.

Mahdizadeh S, Hamid KH, Roudsari MB, Jamil NY, Alfarttoosi KH, Taher SG, et al. Impact of emerging and re-emerging viral infections on periodontitis progression. Arch Microbiol. 2025;208:59. [DOI] [PubMed]

80.

Amano A, Furuta N. Cell entry and exit by periodontal pathogen Porphyromonas gingivalis. J Oral Biosci. 2012;54:54–7. [DOI]

81.

Tribble GD, Lamont RJ. Bacterial invasion of epithelial cells and spreading in periodontal tissue. Periodontol 2000. 2010;52:68–83. [DOI] [PubMed] [PMC]

82.

Jin S, Wu X, Zhang Y, Xu F, Zhen W, Sun Y, et al. Porphyromonas gingivalis links Alzheimer’s disease and periodontal disease: Neuroinflammatory mechanisms and therapeutic implications. hLife. 2026;4:267–88. [DOI]

83.

Mougeot JC, Stevens CB, Paster BJ, Brennan MT, Lockhart PB, Mougeot FK. Porphyromonas gingivalis is the most abundant species detected in coronary and femoral arteries. J Oral Microbiol. 2017;9:1281562. [DOI] [PubMed] [PMC]

84.

Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez JC, Little JW, Loyola-Rodríguez JP. Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. J Clin Periodontol. 2009;36:1004–10. [DOI] [PubMed]

85.

Ardila CM, Granada MI, Guzmán IC. Antibiotic resistance of subgingival species in chronic periodontitis patients. J Periodontal Res. 2010;45:557–63. [DOI] [PubMed]

86.

Rams TE, Sautter JD, van Winkelhoff AJ. Emergence of Antibiotic-Resistant Porphyromonas gingivalis in United States Periodontitis Patients. Antibiotics. 2023;12:1584. [DOI] [PubMed] [PMC]

87.

Wang S, Yan T, Zhang B, Chen Y, Li Z. Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuvants. Vaccines. 2024;12:619. [DOI] [PubMed] [PMC]

88.

Fan X, Qu PY, Luan KF, Sun CY, Ren HP, Sun XH, et al. A cleaved adhesin DNA vaccine targeting dendritic cell against Porphyromonas gingivalis –induced periodontal disease. Mol Oral Microbiol. 2024;39:433–45. [DOI] [PubMed]

89.

Nasiri O, Hajihassani M, Noori Goodarzi N, Fereshteh S, Bolourchi N, Firoozeh F, et al. Reverse vaccinology approach to identify novel and immunogenic targets against Porphyromonas gingivalis: An in silico study. PLoS One. 2022;17:e0273770. [DOI] [PubMed] [PMC]

90.

Shaker B, Ahmad S, Shen J, Kim HW, Na D. Computational Design of a Multi-Epitope Vaccine Against Porphyromonas gingivalis. Front Immunol. 2022;13:806825. [DOI] [PubMed] [PMC]

91.

Wendorff M, Garcia Alvarez HM, Østerbye T, ElAbd H, Rosati E, Degenhardt F, et al. Unbiased Characterization of Peptide-HLA Class II Interactions Based on Large-Scale Peptide Microarrays; Assessment of the Impact on HLA Class II Ligand and Epitope Prediction. Front Immunol. 2020;11:1705. [DOI] [PubMed] [PMC]

92.

Bi J, Jiang L, Zhao J, Zhuang X, Pan L. Targeting peptide–HLA complexes for precision immunotherapy. Trends Pharmacol Sci. 2026;47:603–21. [DOI] [PubMed]

93.

Abdi K, Chen T, Klein BA, Tai AK, Coursen J, Liu X, et al. Mechanisms by which Porphyromonas gingivalis evades innate immunity. PLOS ONE. 2017;12:e0182164. [DOI] [PubMed] [PMC]